🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Targeted Therapy

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer NCT05534438Phase 28 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Stereotactic body radiotherapy A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558Phase 336 sites📍 Gilbert📍 Scottsdale📍 Scottsdale Lyell Immunopharma, Inc. · Tests: rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC NCT06142058n/a1 site📍 Chongqing Xueqin Yang · Tests: RecistTM criteria Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) NCT04427384n/a54 sites📍 Phoenix📍 Little Rock📍 Castro Valley GT Medical Technologies, Inc. · Tests: GammaTile Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors NCT06821048Phase 11 site📍 Hangzhou Weijia Fang, MD · Tests: Intraperitoneal infusion of FAST CEA-targeted CAR-T CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma NCT05948033Phase 1, Phase 21 site📍 Beijing Chinese PLA General Hospital · Tests: CD70-targeting CAR-T cells BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases NCT06794008Phase 21 site📍 Beijing Peking University People's Hospital · Tests: BCMA-CD19 CAR-T therapy CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy. NCT06733610Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: universal allogeneic anti-CD19/BCMA CAR T-cells Universal CAR-T Cell Therapy for MM NCT07248176NA1 site📍 Shanghai Bioray Laboratories · Tests: Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer NCT06631092Phase 1, Phase 22 sites📍 Erlangen📍 Heidelberg NEC Bio B.V · Tests: Oral DNA Vaccine Personalized Medicine for Advanced Biliary Cancer Patients NCT05615818Phase 369 sites📍 Brussels📍 Brussels📍 Edegem UNICANCER · Tests: Futibatinib, Ivosidenib, Zanidatamab, Trastuzumab, Neratinib Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease NCT07542496n/a2 sites📍 Algiers📍 Algiers Société Algérienne de Formation et Recherche en Oncologie A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) NCT05657873Phase 29 sites📍 Miami📍 Basking Ridge📍 Middletown Memorial Sloan Kettering Cancer Center · Tests: L-SABR, Anti-PD-(L)1 based immunotherapy, Platinum based chemotherapy A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors NCT07250386Phase 11 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: CEA-targeted CAR-T (Intravenous), CEA-targeted CAR-T (Intrapleural) Working Memory Training in Patients with Mild Cognitive Impairment NCT06734286NA1 site📍 Phoenix St. Joseph's Hospital and Medical Center, Phoenix · Tests: CogMed A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. NCT04116541Phase 213 sites📍 Angers📍 Bordeaux📍 Caen Centre Leon Berard · Tests: HDM201, Ribociclib, Cabozantinib, Alectinib, Regorafenib A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis NCT06972446Phase 296 sites📍 Peoria📍 Jonesboro📍 Beverly Hills AbbVie · Tests: Lutikizumab, Placebo, Ravagalimab Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma NCT04234022n/a1 site📍 Wolverhampton The Royal Wolverhampton Hospitals NHS Trust · Tests: Zn-DDC, Lanalidomide with Zn-DDC, Pomalidomide with Zn-DDC Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC NCT06726161Phase 1, Phase 213 sites📍 Birmingham📍 Phoenix📍 Orange RayzeBio, Inc. · Tests: RYZ811, RYZ801 CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases NCT06941129Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: UCAR T-cell DETERMINANTS OF IMMUNOTHERAPY EFFICACY IN ENDOMETRIAL CANCER NCT07690540NA1 site📍 Milan European Institute of Oncology · Tests: Prospective exploratory cohort A Study on the Efficacy and Safety of Switching Between Two Targeted Strategies, HP+Chemotherapy and HPy+Chemotherapy, After Treatment Progression in HER-2 Positive Advanced or Metastatic Breast Cancer NCT07455188n/a1 site📍 Zhejiang Zhejiang Cancer Hospital · Tests: Antitumor treatment plan Progression Suppression and Retinal Regression in VEGF-resistant AMD NCT07005323NA3 sites📍 Nagoya📍 Amagasaki📍 Ube PharmaBio Corporation · Tests: Pars plana vitrectomy Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression NCT06975332NA2 sites📍 Warsaw📍 Warsaw Medical University of Warsaw · Tests: Local, targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP (TAT) GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer NCT07489287Phase 11 site📍 Buffalo Roswell Park Cancer Institute · Tests: GB-5267 - IV only, GB-5267 -Combined IV and IP Infusion European Collaborative Multicenter Observational Study: Modular Treatment With PMMR and Targeted Compartmental Pelvic Lymphadenectomy Followed by Therapeutic Pelvic and Paraaortic Lymphadenectomy in Node Positive Disease for Locoregional Control in Endometrial Cancer FIGO Stages I-III NCT04504006n/a1 site📍 Essen Dr. Paul Buderath · Tests: Peritoneal Mesometrial Resetion + Targeted Compartmental Lymphadenectomy (PMMR+TCL) Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma NCT06796543NA3 sites📍 Washington D.C.📍 Baltimore📍 Minneapolis Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: Consolidative radiation therapy (cRT) Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma NCT05842174Phase 1, Phase 21 site📍 Philadelphia VA Office of Research and Development · Tests: Hydroxychloroquine, Lipiodol, Placebo Evaluation of Safety and Effectiveness of TLD Radiofrequency Ablation in the Treatment of COPD NCT05799664NA1 site📍 Chengdu Hangzhou Broncus Medical Co., Ltd. · Tests: TLD, Sham TLD procedure, Standard of care A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma NCT06642792Phase 1, Phase 21 site📍 Beijing Akeso · Tests: AK129, AK117
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy